Galectin Therapeutics Inc (GALT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galectin Therapeutics Inc (GALT) has a cash flow conversion efficiency ratio of 0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.54 Million) by net assets ($-125.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Galectin Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Galectin Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Galectin Therapeutics Inc carry for a breakdown of total debt and financial obligations.
Galectin Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galectin Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kian Shen Corp
TW:1525
|
-0.021x |
|
Resources Connection Inc
NASDAQ:RGP
|
0.082x |
|
Unic Technology
TWO:5452
|
0.064x |
|
Aurum Resources Ltd
AU:AUE
|
0.014x |
|
CF Bankshares Inc
NASDAQ:CFBK
|
0.014x |
|
D O Green Technologies Bhd
KLSE:7204
|
0.022x |
|
Element 29 Resources Inc
V:ECU
|
-0.020x |
|
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.
IS:ONCSM
|
0.126x |
Annual Cash Flow Conversion Efficiency for Galectin Therapeutics Inc (2000–2024)
The table below shows the annual cash flow conversion efficiency of Galectin Therapeutics Inc from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see GALT market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-103.07 Million | $-41.77 Million | 0.405x | -25.95% |
| 2023-12-31 | $-60.24 Million | $-32.97 Million | 0.547x | -43.27% |
| 2022-12-31 | $-32.19 Million | $-31.06 Million | 0.965x | +110.38% |
| 2021-12-31 | $2.62 Million | $-24.31 Million | -9.292x | -991.22% |
| 2020-12-31 | $24.19 Million | $-20.60 Million | -0.852x | -257.90% |
| 2019-12-31 | $45.59 Million | $-10.85 Million | -0.238x | +83.88% |
| 2018-12-31 | $6.90 Million | $-10.18 Million | -1.476x | +88.92% |
| 2017-12-31 | $1.19 Million | $-15.89 Million | -13.321x | -875.39% |
| 2016-12-31 | $12.02 Million | $-16.41 Million | -1.366x | -101.43% |
| 2015-12-31 | $25.05 Million | $-16.98 Million | -0.678x | -52.64% |
| 2014-12-31 | $27.97 Million | $-12.43 Million | -0.444x | +51.17% |
| 2013-12-31 | $8.23 Million | $-7.48 Million | -0.910x | +3.97% |
| 2012-12-31 | $7.92 Million | $-7.50 Million | -0.947x | +26.61% |
| 2011-12-31 | $4.40 Million | $-5.68 Million | -1.291x | -170.49% |
| 2010-12-31 | $-1.69 Million | $-3.10 Million | 1.831x | +110.44% |
| 2009-12-31 | $-4.47 Million | $-3.89 Million | 0.870x | -91.25% |
| 2008-12-31 | $-469.00K | $-4.67 Million | 9.947x | +430.44% |
| 2007-12-31 | $-2.92 Million | $-5.48 Million | 1.875x | -99.39% |
| 2006-12-31 | $-22.00K | $-6.76 Million | 307.136x | +18060.99% |
| 2005-12-31 | $3.58 Million | $-6.13 Million | -1.710x | -172.85% |
| 2004-12-31 | $10.11 Million | $-6.33 Million | -0.627x | -15.08% |
| 2003-12-31 | $7.62 Million | $-4.15 Million | -0.545x | +70.49% |
| 2002-12-31 | $1.62 Million | $-2.98 Million | -1.845x | -24.69% |
| 2001-12-31 | $1.22 Million | $-1.80 Million | -1.480x | +17.78% |
| 2000-12-31 | $50.00K | $-90.00K | -1.800x | -- |
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 cl… Read more